Nimotuzumab + Temozolomide
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma
Trial Timeline
Aug 18, 2010 → Mar 23, 2017
NCT ID
NCT03388372About Nimotuzumab + Temozolomide
Nimotuzumab + Temozolomide is a phase 2 stage product being developed by Sun Pharmaceutical for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03388372. Target conditions include Glioblastoma.
What happened to similar drugs?
1 of 18 similar drugs in Glioblastoma were approved
Approved (1) Terminated (1) Active (16)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03388372 | Phase 2 | Completed |
Competing Products
20 competing products in Glioblastoma